Literature DB >> 35880135

The Elevation of Pancreatic Enzymes in Serum and Their Distribution at Different Stages of Renal Insufficiency Among Diabetic Patients Attending Goba Referral Hospital.

Tadele Regasa1, Yohannes Dinku1, Bereket Gezahegn1, Zegeye Feleke2, Zegeye Regassa2, Ayele Mamo1, Tesfaye Assefa2, Habtamu Gezahegn1, Damtew Solomon1, Daniel Atlaw1, Mengistu Dessie3.   

Abstract

Introduction: Acute pancreatitis is auto-cell destruction that is manifested by increased leakage of amylase and lipase into circulation. During pancreatitis, the activity of serum amylase and lipase is elevated three times above the upper limit of the normal range. This elevation was observed in both prediabetic and diabetic patients. Severe acute pancreatitis can result in acute kidney injury and other multi-organ dysfunction, which is one of the reasons for death. Objective: This study aimed to evaluate the elevation of serum amylase and lipase and their distribution at different stages of renal insufficiency among diabetic patients.
Methods: This study included 286 diabetic patients (36 type 1 and 250 type 2), and data were collected from May 1 to June 30, 2019. The study design used was an institution-based cross-sectional study. A face-to-face interview was used to collect data, and serum creatinine, amylase, and lipase levels were measured using a chemistry analyzer. For data entry and statistical analysis, respectively, Epidata software version 3.02 and SPSS version 21 were used.
Results: The mean serum amylase among diabetic patients suffering from G3b and G4 was 106.79 IU/L ± 118.18 IU/L and 104.85 ± 90.42 IU/L, respectively. Their mean serum lipase activity was 105.07 IU/L ± 127.54 IU/L and 106.98 IU/L ± 88.35 IU/L, respectively. Serum lipase activity was elevated above the normal range and three times above the upper limit of the normal range with a magnitude of 11.2% and 4.2%, respectively. Similarly, 9.1% and 0.7% of diabetic patients had increased serum amylase above the normal range and three-fold above the normal range, respectively.
Conclusion: As glomerular filtration decreases, particularly in moderate-to-severe chronic kidney disease, serum amylase and lipase activity rise above the upper limit.
© 2022 Regasa et al.

Entities:  

Keywords:  acute pancreatitis; chronic kidney disease; diabetes mellitus; serum amylase; serum lipase

Year:  2022        PMID: 35880135      PMCID: PMC9307908          DOI: 10.2147/DMSO.S363714

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.249


  27 in total

1.  Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes.

Authors:  C J Girman; T D Kou; B Cai; C M Alexander; E A O'Neill; D E Williams-Herman; L Katz
Journal:  Diabetes Obes Metab       Date:  2010-09       Impact factor: 6.577

2.  Severity and natural history of acute pancreatitis in diabetic patients.

Authors:  Haq Nawaz; Michael O'Connell; Georgios I Papachristou; Dhiraj Yadav
Journal:  Pancreatology       Date:  2015-04-04       Impact factor: 3.996

Review 3.  Measured GFR as a confirmatory test for estimated GFR.

Authors:  Lesley A Stevens; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

Review 4.  The epidemiology of pancreatitis and pancreatic cancer.

Authors:  Dhiraj Yadav; Albert B Lowenfels
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 5.  Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021.

Authors:  Lesley A Inker; Silvia Titan
Journal:  Am J Kidney Dis       Date:  2021-09-11       Impact factor: 8.860

Review 6.  Acute pancreatitis in chronic kidney disease--a common but often misunderstood combination.

Authors:  Vishal Golay; Arpita Roychowdhary
Journal:  Ren Fail       Date:  2012-09-24       Impact factor: 2.606

Review 7.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

Authors:  Lesley A Inker; Brad C Astor; Chester H Fox; Tamara Isakova; James P Lash; Carmen A Peralta; Manjula Kurella Tamura; Harold I Feldman
Journal:  Am J Kidney Dis       Date:  2014-03-16       Impact factor: 8.860

8.  LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Authors:  William M Steinberg; Michael A Nauck; Bernard Zinman; Gilbert H Daniels; Richard M Bergenstal; Johannes F E Mann; Lasse Steen Ravn; Alan C Moses; Mette Stockner; Florian M M Baeres; Steven P Marso; John B Buse
Journal:  Pancreas       Date:  2014-11       Impact factor: 3.327

Review 9.  Global epidemiology and holistic prevention of pancreatitis.

Authors:  Maxim S Petrov; Dhiraj Yadav
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

10.  Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes.

Authors:  Jaret Malloy; Kate Gurney; Kevin Shan; Ping Yan; Steve Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2012-12-17       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.